Top

Published in:

01-07-2008 | Preclinical Study

Antibodies to 46-kDa retinal antigen in a patient with breast carcinoma and cancer-associated retinopathy

Authors: Maria Ejma, Marta Misiuk-Hojło, Wojciech A. Gorczyca, Ryszard Podemski, Stanisław Szymaniec, Marianna Kuropatwa, Jadwiga Rogozińska-Szczepka, Wiesława Bartnik

Published in: Breast Cancer Research and Treatment | Issue 2/2008

Abstract

Cancer-associated retinopathy (CAR) is a rare paraneoplastic syndrome usually associated with small-cell lung carcinoma and serum autoantibodies against recoverin. We report the breast cancer woman with visual impairments and electrophysiological abnormalities characteristic of CAR. Her serum contained high-titer antibodies against α-enolase but not against other retinal proteins. This suggests that anti-enolase antibodies could be responsible for the development of CAR symptoms.

Khan N, Huang JJ, Foster S (2006) Cancer-associated retinopathy (CAR): an autoimmune-mediated paraneoplastic syndrome. Seminar Ophthalm 21:135–141CrossRef

Subramanian L, Polans AS (2004) Cancer-related diseases of the eye: the role of calcium and calcium-binding proteins. Biochem Biophys Res Commun 4:1153–1165CrossRef

Chan JW (2003) Paraneoplastic retinopathies and optic neuropathies. Surv Ophthalmol 48:12–38PubMedCrossRef

Damek DM (2005) Paraneoplastic retinopathy/optic neuropathy. Curr Treat Opin Neurol 7:57–67CrossRef

Bataller L, Dalmau J (2004) Neuro-ophthalmology and paraneoplastic syndromes. Curr Opin Neurol 17:3–8PubMedCrossRef

Gatti G, Simsek S, Kurne A et al (2003) Paraneoplastic neurological disorders in breast cancer. Breast 12:203–207PubMedCrossRef

Rojas-Marcos I, Rousseau A, Keime-Guibert F et al (2003) Spectrum of paraneoplastic neurologic disorders in women with breast and gynecologic cancer. Medicine 82:216–223PubMedCrossRef

Wickremasinghe S, Dansingani KK, Tranos P et al (2007) Ocular presentations of breast cancer. Acta Ophthalmol Scand 85:133–142PubMedCrossRef

Savchenko MS, Bazhin AV, Shifrina ON et al (2003) Antirecoverin autoantibodies in the patient with non-small cell lung cancer but without cancer-associeted retinopathy. Lung Cancer 41:363–367PubMedCrossRef

10.

Adamus G, Aptsiauri N, Guy J et al (1996) The occurrence of serum autoantibodies against enolase in cancer-associated retinopathy. Clin Immunol Immunopathol 78:120–129PubMedCrossRef

11.

Weleber RG, Watzke RC, Shults WT et al (2005) Clinical and electrophysiologic characterization of paraneoplastic and autoimmune retinopathies associated with antienolase antibodies. Am J Ophthalmol 139:780–794PubMedCrossRef

12.

Gorczyca WA, Ejma M, Witkowska D et al (2004) Retinal antigens are recognized by antibodies present in sera of patients with multiple sclerosis. Ophthalmic Res 36:20–23CrossRef

13.

Jankowska R, Witkowska D, Porębska I et al (2004) Serum antibodies to retinal antigens in lung cancer and sarcoidosis. Pathobiology 71:323–328PubMedCrossRef

14.

Adamus G (2003) Autoantibody-induced apoptosis as a possible mechanism of autoimmune retinopathy. Autoimmun Rev 2:63–68PubMedCrossRef

15.

Kobayashi M, Ikezoe T, Uemura Y et al (2007) Establishment of a novel small cell lung carcinoma cell line with specific recoverine expression from a patient with cancer-associated retinopathy. Lung Cancer 56:319–326PubMedCrossRef

16.

Ohguro H, Yokoi Y, Ohguro I et al (2004) Clinical and immunological aspects of cancer-associated rtinopathy. Am J Ophthalmol 137:1117–1119PubMedCrossRef

17.

Pancholi V (2001) Multifunctional α-enolase: its role in diseases. Cellular and Molecular Life Sciences 58:902–920PubMedCrossRef

18.

Terrier B, Degand N, Guilpain P (2007) Alpha-enolase: A target of antibodies in infectious and autoimmune diseases. Autoimmun Rev 6:176–182PubMedCrossRef

Title: Antibodies to 46-kDa retinal antigen in a patient with breast carcinoma and cancer-associated retinopathy
Authors: Maria Ejma
Marta Misiuk-Hojło
Wojciech A. Gorczyca
Ryszard Podemski
Stanisław Szymaniec
Marianna Kuropatwa
Jadwiga Rogozińska-Szczepka
Wiesława Bartnik
Publication date: 01-07-2008
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-007-9721-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2008

Effects of IL-12 gene therapy on spontaneous transgenic and transplanted breast tumors

Breast cancer in elderly women. Optimizing the treatment

Does high surgeon and hospital surgical volume raise the five-year survival rate for breast cancer? A population-based study

Akt plays an important role in breast cancer cell chemotaxis to CXCL12

Lymphedema in women with breast cancer: characteristics of patients screened for a randomized trial

Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and breast cancer risk in Africans

Keynote webinar | Spotlight on antibody–drug conjugates in cancer